Predictive value of repeated versus single N-terminal pro B-type natriuretic peptide measurements early after-myocardial infarction

PACE - Pacing and Clinical Electrophysiology

Volumn 32, Issue SUPPL. 1, 2009, Pages

  Sandhu, Sabrina ^a   Har, Bryan J ^a   Aggarwal, Sandeep G ^a   Kavanagh, Katherine M ^a   Ramadan, Darlene ^a   Exner, Derek V ^a,b  

^a LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^b NONE   (Canada)

Author keywords

Actuarial survival; Myocardial infarction; Natriuretic peptide; Risk stratification

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; CARDIOVASCULAR RISK; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; SENSITIVITY ANALYSIS;

AGED; AGED, 80 AND OVER; ALBERTA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 60849126691     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2008.02259.x     Document Type: Conference Paper

References (10)

1. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003 362 : 316 322.
2. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002 105 : 2392 2397.
3. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002 106 : 2913 2918.
4. Tapanainen JM, Lindgren KS, Makikallio TH, Vuolteenaho O, Leppaluoto J, Huikuri HV. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2004 43 : 757 763.
5. Miller WL, Hartman KA, Burritt MF, Grill DE, Rodeheffer RJ, Burnett JC Jr., Jaffe AS. Serial biomarker measurements in ambulatory patients with chronic heart failure: The importance of change over time. Circulation 2007 116 : 249 257.
6. Exner DV, Kavanagh KM, Slawnych MP, Mitchell LB, Ramadan D, Aggarwal SG, Noullett C, et al. Noninvasive risk assessment early after a myocardial infarction the REFINE study. J Am Coll Cardiol 2007 50 : 2275 2284.
7. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003 107 : 1278 1283.
8. Yu H, Oswald H, Gardiwal A, Lissel C, Klein G. Comparison of N-terminal pro-brain natriuretic peptide versus electrophysiologic study for predicting future outcomes in patients with an implantable cardioverter defibrillator after myocardial infarction. Am J Cardiol 2007 100 : 635 639.
9. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, Tanasijevic M, Hall C, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 2004 44 : 1988 1995.
10. Arakawa N, Nakamura M, Aoki H, Hiramori K. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol 1996 27 : 1656 1661.